Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Staten Island, NY, US. The stock last traded at $1.33, down 4.32% on the session, giving a market capitalisation of $5.7M. On trailing twelve-month figures it carries a trailing P/E of -0.37, a net margin of 0.0%. Its beta of -2.02 implies it has historically moved less than the broad market.
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals, Inc. is most often compared with the following Healthcare names: